Literature DB >> 15748875

Spinal nerve ligation increases alpha2-adrenergic receptor G-protein coupling in the spinal cord.

Carsten Bantel1, James C Eisenach, Frederic Duflo, Joseph R Tobin, Steven R Childers.   

Abstract

Intrathecal and epidural administration of the alpha2-adrenergic receptor agonist clonidine in humans results in analgesia to both acute nociceptive and chronic neuropathic pain. The potency of clonidine increases with hypersensitivity to mechanical stimuli after nerve injury, although the reasons for this change are unknown. In the present study, we tested the hypothesis that peripheral nerve injury alters either spinal alpha2-adrenergic receptor-mediated G-protein activity or alpha2-adrenergic receptor number. Rats were randomized to left spinal nerve ligation (SNL) or sham surgery. Tactile hypersensitivity in the hindpaw was confirmed and lumbar spinal cords were removed for binding assays. To examine agonist-induced G-protein coupling, [35S]GTP gamma S binding experiments were performed in spinal cord membranes and sections using norepinephrine as an alpha2-adrenergic agonist. SNL was associated with an increase in maximal efficacy, but not potency, of norepinephrine-stimulated [35S]GTP gamma S binding in dorsal horn. SNL had no effect on basal [35S]GTP gamma S binding or on muscarinic cholinergic-stimulated [35S]GTP gamma S binding. [35S]GTP gamma S autoradiography showed that this increase in alpha2-adrenergic-activated G-proteins occurred both ipsilateral and contralateral to SNL surgery. SNL did not alter total alpha2-adrenergic receptor number or affinity to [3H]-rauwolscine binding, and displacement studies with the alpha2A-adrenergic antagonist BRL44408 revealed that most of the binding was associated with the alpha2A-adrenergic subtype. These data suggest that the increased potency of clonidine in neuropathic pain could reflect increased efficiency of G-protein coupling from spinal alpha2-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748875     DOI: 10.1016/j.brainres.2005.01.016

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

1.  Src family kinases mediate the inhibition of substance P release in the rat spinal cord by μ-opioid receptors and GABA(B) receptors, but not α2 adrenergic receptors.

Authors:  Guohua Zhang; Wenling Chen; Juan Carlos G Marvizón
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

Review 2.  The noradrenergic locus coeruleus as a chronic pain generator.

Authors:  Bradley K Taylor; Karin N Westlund
Journal:  J Neurosci Res       Date:  2016-09-29       Impact factor: 4.164

3.  Activation of NK₁ receptors in the locus coeruleus induces analgesia through noradrenergic-mediated descending inhibition in a rat model of neuropathic pain.

Authors:  Y Muto; A Sakai; A Sakamoto; H Suzuki
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  Spinal alpha 2-adrenoceptor-mediated analgesia in neuropathic pain reflects brain-derived nerve growth factor and changes in spinal cholinergic neuronal function.

Authors:  Ken-ichiro Hayashida; James C Eisenach
Journal:  Anesthesiology       Date:  2010-08       Impact factor: 7.892

Review 5.  Spinal α2 -adrenoceptors and neuropathic pain modulation; therapeutic target.

Authors:  Zahra Bahari; Gholam Hossein Meftahi
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

6.  Depletion of endogenous noradrenaline does not prevent spinal cord plasticity following peripheral nerve injury.

Authors:  Ken-Ichiro Hayashida; Christopher M Peters; Silvia Gutierrez; James C Eisenach
Journal:  J Pain       Date:  2011-12-11       Impact factor: 5.820

7.  Proteomic and bioinformatic profile of primary human oral epithelial cells.

Authors:  Santosh K Ghosh; Elizabeth Yohannes; Gurkan Bebek; Aaron Weinberg; Bin Jiang; Belinda Willard; Mark R Chance; Michael T Kinter; Thomas S McCormick
Journal:  J Proteome Res       Date:  2012-10-16       Impact factor: 4.466

Review 8.  The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Y Kögel
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  Potentiation of spinal alpha(2)-adrenoceptor analgesia in rats deficient in TRPV1-expressing afferent neurons.

Authors:  Shao-Rui Chen; Hao-Min Pan; Timothy E Richardson; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2007-03-24       Impact factor: 5.250

Review 10.  Spinal inhibitory neurotransmission in neuropathic pain.

Authors:  Bradley K Taylor
Journal:  Curr Pain Headache Rep       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.